Importantly for people with ME/CFS, the timing of the second CPET coincides with debilitating exacerbation of pain and fatigue (Light et al.,
2012; White, Light, Hughen, Vanhaitsma, & Light,
2012), potentially further impairing the ability to provide sufficient peak effort. Conversely, our recent work with GWI patients found that the frequency of veterans experiencing symptom exacerbation and the magnitude of the change 24 hr after 30 min of steady‐state cycling at 70% heart rate reserve was considerably lower than what has been reported in ME/CFS (Lindheimer et al.,
2020). The high rate of submaximal performance during a maximal test among individuals with ME/CFS (De Becker, Roeykens, Reynders, McGregor, & De Meirleir,
2000), paucity of data on CPET test–retest reliability in this population, as well as our observation of a less frequent and severe PEM response in GWI (Lindheimer et al.,
2020) raises doubt about whether test–retest reliability observed here generalizes to ME/CFS. For these reasons, a separate study characterizing the test–retest reliability of CPET may be warranted in ME/CFS before it can be confidently assumed that the 2‐day CPET protocol affords an objective measure of PEM in this population (Stevens et al.,
2018).